Genetic variants in RhoA and ROCK1 genes are associated with the development, progression and prognosis of prostate cancer

Kang Liu; Xiao Li; Jie Wang; Yichun Wang; Huiyu Dong; Jie Li

doi:10.18632/oncotarget.15197

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Genetic variants in RhoA and ROCK1 genes are associated with the development, progression and prognosis of prostate cancer

Kang Liu, Xiao Li, Jie Wang, Yichun Wang, Huiyu Dong and Jie Li _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:19298-19309. https://doi.org/10.18632/oncotarget.15197

Metrics: PDF 1601 views | HTML 2564 views | ?

Abstract

Kang Liu1,*, Xiao Li2,*, Jie Wang1,*, Yichun Wang1, Huiyu Dong1, Jie Li1,*

1Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

2Department of Urology, The Affiliated Cancer Hospital of Jiangsu Province of Nanjing Medical University, Nanjing, China

*These authors contributed equally to this work

Correspondence to:

Jie Li, email: [email protected]

Keywords: genetic variants, RhoA/ROCK1 pathway, prostate cancer, prognosis, biochemical recurrence

Received: July 27, 2016 Accepted: January 03, 2017 Published: February 08, 2017

ABSTRACT

The contribution of genetic variants in RhoA and ROCK1 genes towards prostate cancer risk has not been reported before. We genotyped six potentially functional genetic variants in a case-control study of 1699 subjects. Overall, we found rs2410 mutant allele and rs2269736 wild allele were risk factors for prostate cancer. Individuals carrying more than two risk alleles were exposed to hazard of prostate cancer. In addition, we demonstrated that the risk of biochemical recurrence might be linked with clinico-pathological characteristics and also genetic factors. Unfortunately, no associations were observed between all polymorphisms and clinico-pathological characteristics. Moreover, no genotype was found as significant independent prognostic predictor for biochemical recurrence survival in Multivariate Cox regression analysis after Bonferroni correction. Our study is the first to clarify the relations of genetic variants of RhoA and ROCK1 genes with development, progression and prognosis of prostate cancer. These variants may be promising novel biomarkers to facilitate clinical treatment decision-making.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15197

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Genetic variants in RhoA and ROCK1 genes are associated with the development, progression and prognosis of prostate cancer

Abstract